Longitudinal serum proteomics identifies inflammatory and metabolic pathways in hypertensive nephrosclerosis progression.

IF 2.8 3区 医学 Q2 BIOCHEMICAL RESEARCH METHODS
Ole Petter Nordbø, Øystein Eikrem, Philip A Kalra, Hans-Peter Marti, Jessica Furriol
{"title":"Longitudinal serum proteomics identifies inflammatory and metabolic pathways in hypertensive nephrosclerosis progression.","authors":"Ole Petter Nordbø, Øystein Eikrem, Philip A Kalra, Hans-Peter Marti, Jessica Furriol","doi":"10.1186/s12014-025-09537-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hypertensive nephrosclerosis (HN) is a major cause of end-stage renal disease; however, few longitudinal studies have employed serum proteomics to document its progression. This study aimed to identify potential circulating biomarkers indicative of disease progression in HN by performing serum proteomic analysis at two time points in patients with progressive and stable disease.</p><p><strong>Methods: </strong>Forty-one patients diagnosed with HN were recruited from the UK Salford Kidney Study, with serum samples collected at baseline and follow-up (1.5-10 years after baseline). Twenty-five patients experienced stable disease course, while 16 patients experienced progressive disease. Proteomics was performed via tandem mass tag labelling and liquid chromatography-tandem mass-spectrometry (LC-MS). Pathway analysis was performed on all significantly abundant proteins, as was network analysis of circulating proteins that are abundant in the kidney according to the Human Protein Atlas.</p><p><strong>Results: </strong>Pathway analysis revealed significant enrichment in pathways related to inflammation and infection, including complement and coagulation cascades, as well as metabolic processes in patients with disease progression. Marker abundance levels related to adhesion and the ECM were also altered in progresssive disease follow-up, compared to stable disease follow-up.</p><p><strong>Conclusion: </strong>The observed changes in inflammatory and adhesion-related pathways may offer valuable insights into the mechanisms driving HN progression and potential targets for intervention.</p>","PeriodicalId":10468,"journal":{"name":"Clinical proteomics","volume":"22 1","pages":"17"},"PeriodicalIF":2.8000,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12054191/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical proteomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12014-025-09537-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Hypertensive nephrosclerosis (HN) is a major cause of end-stage renal disease; however, few longitudinal studies have employed serum proteomics to document its progression. This study aimed to identify potential circulating biomarkers indicative of disease progression in HN by performing serum proteomic analysis at two time points in patients with progressive and stable disease.

Methods: Forty-one patients diagnosed with HN were recruited from the UK Salford Kidney Study, with serum samples collected at baseline and follow-up (1.5-10 years after baseline). Twenty-five patients experienced stable disease course, while 16 patients experienced progressive disease. Proteomics was performed via tandem mass tag labelling and liquid chromatography-tandem mass-spectrometry (LC-MS). Pathway analysis was performed on all significantly abundant proteins, as was network analysis of circulating proteins that are abundant in the kidney according to the Human Protein Atlas.

Results: Pathway analysis revealed significant enrichment in pathways related to inflammation and infection, including complement and coagulation cascades, as well as metabolic processes in patients with disease progression. Marker abundance levels related to adhesion and the ECM were also altered in progresssive disease follow-up, compared to stable disease follow-up.

Conclusion: The observed changes in inflammatory and adhesion-related pathways may offer valuable insights into the mechanisms driving HN progression and potential targets for intervention.

纵向血清蛋白质组学鉴定高血压肾硬化进展中的炎症和代谢途径。
背景:高血压性肾硬化(HN)是终末期肾脏疾病的主要病因;然而,很少有纵向研究使用血清蛋白质组学来记录其进展。本研究旨在通过在进展性和稳定期HN患者的两个时间点进行血清蛋白质组学分析,确定指示疾病进展的潜在循环生物标志物。方法:从英国索尔福德肾脏研究中招募41名诊断为HN的患者,在基线和随访(基线后1.5-10年)收集血清样本。病程稳定25例,病程进展16例。蛋白质组学通过串联质标签和液相色谱-串联质谱(LC-MS)进行。对所有显著丰富的蛋白质进行通路分析,根据人类蛋白质图谱对肾脏中丰富的循环蛋白质进行网络分析。结果:通路分析显示炎症和感染相关通路显著富集,包括补体和凝血级联,以及疾病进展患者的代谢过程。与稳定的疾病随访相比,进展性疾病随访中与粘附和ECM相关的标志物丰度水平也发生了变化。结论:观察到的炎症和粘连相关通路的变化可能为推动HN进展的机制和潜在的干预靶点提供有价值的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical proteomics
Clinical proteomics BIOCHEMICAL RESEARCH METHODS-
CiteScore
5.80
自引率
2.60%
发文量
37
审稿时长
17 weeks
期刊介绍: Clinical Proteomics encompasses all aspects of translational proteomics. Special emphasis will be placed on the application of proteomic technology to all aspects of clinical research and molecular medicine. The journal is committed to rapid scientific review and timely publication of submitted manuscripts.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信